ArticleNeurosurgery practice2025
Evaluation of Liposomal Bupivacaine Use in Elective Cerebral Aneurysm Surgery.
Article in Neurosurgery practice, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesLiposomal bupivacaine (LB) is a long-lasting formulation of local anesthetic which can be effective up to 72 hours postoperatively. Although it is approved for postsurgical analgesia through local wound infiltration and has frequently been used in spine surgery, there is little evidence regarding the effect of LB on cranial surgery postoperative care.
methodsWe retrospectively reviewed 79 patients who underwent elective craniotomy for unruptured anterior circulation aneurysms, of which 44 were given LB and 35 were not. Postoperative pain scores, length of stay (LOS), opioid use, and cost of pain medication were all obtained from the patients' charts and analyzed.
resultsThere was no significant difference in initial pain scores, average pain scores, opioid use, or intensive care unit or overall LOS. However, the total cost of pain medication when taking into account the cost of LB was significantly higher in the LB group compared with the control group ($647.84 ± 122.50 compared with $284.77 ± 113.44;
conclusionOur data illustrate that LB does not seem to affect average pain score, total opioid use, opioid cost, or LOS but does seem to be associated with an overall increase in total cost of pain medication owing to the significant cost of LB. We suspect that although pain control is important in cranial surgery, the effect of LB is not substantial enough to affect overall pain control in these patients and is not a primary driver of hospitalization. However, further prospective, randomized studies would be helpful to evaluate the overall benefit of LB on cranial surgery outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.